Teva to present further results of twenty-year open-label extension study of glatiramer acetate 20 mg daily for relapsing-remitting multiple sclerosis Teva Pharmaceutical Industries, 3 Oct 2013 Accessed on 4 Oct 2013 from http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=1861304. CommentRecommendBookmarkWatch